Free Trial

BridgeBio Pharma (BBIO) News Today

BridgeBio Pharma logo
$23.04 +0.50 (+2.22%)
(As of 11/20/2024 ET)
BridgeBio Pharma (BBIO) Gets a Buy from Scotiabank
Equities Analysts Offer Predictions for BBIO FY2024 Earnings
BridgeBio reports open-label extension data on acoramidis in ATTR-CM
BridgeBio Pharma, Inc. stock logo
First Turn Management LLC Makes New $10.18 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
First Turn Management LLC acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 399,781 shares of the company's stock, va
BridgeBio Pharma, Inc. stock logo
Royce & Associates LP Takes $3.11 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Royce & Associates LP bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 121,955 shares of the company's stock, valued at approximately $3
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $45.00 at Scotiabank
BridgeBio Pharma, Inc. stock logo
FY2024 EPS Forecast for BridgeBio Pharma Reduced by Analyst
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2024 earnings estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now forecasts t
BridgeBio Pharma, Inc. stock logo
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has earned an average rating of "Moderate Buy" from the fifteen analysts that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The
BridgeBio price target raised to $45 from $44 at Scotiabank
BridgeBio Pharma, Inc. stock logo
Scotiabank Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price
Scotiabank raised their price target on BridgeBio Pharma from $44.00 to $45.00 and gave the company a "sector outperform" rating in a report on Friday.
BridgeBio Pharma, Inc. stock logo
Leerink Partnrs Has Negative Outlook of BBIO FY2024 Earnings
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Research analysts at Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report released on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now expects that the company will po
BridgeBio Pharma, Inc. stock logo
Leerink Partnrs Has Negative Outlook of BBIO FY2028 Earnings
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for BridgeBio Pharma in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now forecasts tha
BridgeBio Pharma Reports Quarterly Loss Amid Restructuring
Evercore ISI Remains a Buy on BridgeBio Pharma (BBIO)
BridgeBio Pharma (BBIO) Gets a Hold from Oppenheimer
TD Cowen Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
BridgeBio Pharma, Inc. stock logo
WCM Investment Management LLC Purchases 86,987 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
WCM Investment Management LLC lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 49.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 263,679 shares of the company's stock after acquiring an additional 86,987
BridgeBio Dives on Revealing Case Study
BridgeBio announces publication on impact of biomedical innovation
BridgeBio Pharma, Inc. stock logo
Emerald Advisers LLC Has $28.10 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Emerald Advisers LLC lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 65.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,103,508 shares of the company's stock after buying an ad
BridgeBio Pharma, Inc. stock logo
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 8.3% - Here's Why
BridgeBio Pharma (NASDAQ:BBIO) Trading 8.3% Higher - Here's Why
BridgeBio Pharma, Inc. stock logo
HC Wainwright Reiterates "Buy" Rating for BridgeBio Pharma (NASDAQ:BBIO)
HC Wainwright reissued a "buy" rating and set a $43.00 target price on shares of BridgeBio Pharma in a research note on Friday.
BridgeBio Pharma, Inc. stock logo
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and thirteen have assigned a bu
BridgeBio Pharma, Inc. stock logo
BridgeBio Pharma (NASDAQ:BBIO) PT Lowered to $46.00 at Leerink Partners
Leerink Partners decreased their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating for the company in a report on Thursday.
BridgeBio Pharma, Inc. stock logo
Equities Analysts Offer Predictions for BridgeBio Pharma, Inc.'s Q3 2024 Earnings (NASDAQ:BBIO)
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Leerink Partnrs decreased their Q3 2024 earnings per share (EPS) estimates for BridgeBio Pharma in a note issued to investors on Monday, October 14th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will pos
BridgeBio Pharma, Inc. stock logo
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at Scotiabank
Scotiabank initiated coverage on shares of BridgeBio Pharma in a research report on Wednesday. They set a "sector outperform" rating on the stock.
BridgeBio Pharma, Inc. stock logo
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 4.7% - Should You Buy?
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 4.7% - Here's What Happened
BridgeBio Pharma, Inc. stock logo
BridgeBio Pharma (NASDAQ:BBIO) Shares Down 4.6% - Here's What Happened
BridgeBio Pharma (NASDAQ:BBIO) Shares Down 4.6% - Time to Sell?
BridgeBio Pharma, Inc. stock logo
Marshall Wace LLP Acquires Shares of 30,849 BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Marshall Wace LLP bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 30,849 shares of the company's stock, valued at approximately $781,000. Several other large investors
BridgeBio Pharma, Inc. stock logo
Algert Global LLC Has $1.42 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Algert Global LLC trimmed its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 37.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,848 shares of the company's stock after
Get BridgeBio Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

BBIO Media Mentions By Week

BBIO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BBIO
News Sentiment

0.17

0.45

Average
Medical
News Sentiment

BBIO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BBIO Articles
This Week

32

7

BBIO Articles
Average Week

Get BridgeBio Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BBIO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners